SEPN vs CLDX
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
SEPN · Septerna$48.85 ▲ 3.17%
CLDX · Celldex Therapeutics$29.87 ▲ 5.66%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- SEPN +169.9%
- CLDX +31.8%
Head to head
| Metric | SEPN | CLDX |
|---|---|---|
| Price | $48.85 | $29.87 |
| Change today | ▲ 3.17% | ▲ 5.66% |
| Market cap | $2.28B | $2.35B |
| Return, 3 months | +25.7% | -30.5% |
| Return, year to date | +75.2% | +10.0% |
| Return, 1 year | +163.9% | +30.4% |
| P/E (TTM) | -92.2 | -7.0 |
| P/B | 5.9 | 3.6 |
| P/E percentile vs own 5y | 4th | 97th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +22,375.6% | -97.0% |
| Net profit growth (YoY) | +47.5% | -29.9% |
| Gross margin | – | – |
| Operating margin | -56.7% | -206,220.3% |
| Net margin | -24.5% | -190,220.9% |
| Return on equity | -6.3% | -43.9% |
| Analyst target vs. price | +8.2% | +133.7% |
| Analyst buy share | 100% | 100% |
| RSI (14) | 73 | 47 |
| 30-day volatility | 54.3% | 50.1% |
| Max drawdown, 1 year | -26.0% | -38.6% |
| Trend read | Strong uptrend | Leaning bullish |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- CLDX is the largest of the group by market value.
- SEPN has returned the most over the past year.
- SEPN carries the lowest trailing P/E.
- SEPN is growing revenue fastest.
- SEPN keeps the most profit per dollar of sales.
- CLDX has been the calmest stock over the last 30 days.